Bio­Marin holds the line on bleeds with 4-year val­rox up­date on he­mo­phil­ia A — but what's this about an­oth­er de­cline in Fac­tor 8 lev­els?

Bio­Marin has post­ed some top-line re­sults for their 4-year fol­lowup on the most ad­vanced gene ther­a­py for he­mo­phil­ia A — ex­tend­ing its streak on keep­ing a hand­ful of pa­tients free of bleeds and off Fac­tor VI­II ther­a­py, but like­ly stir­ring fresh wor­ries over a con­tin­ued drop in Fac­tor VI­II lev­els.

We just don’t know how big a drop.

We’ll see more da­ta when the re­sults are pre­sent­ed at the World Fed­er­a­tion of He­mo­phil­ia in a cou­ple of weeks. But in a state­ment out Sun­day night, Bio­Marin $BM­RN re­port­ed that none of the pa­tients re­quired Fac­tor VI­II treat­ment, adding:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER